Edition:
United Kingdom

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

4.53USD
4:08pm BST
Change (% chg)

$-0.08 (-1.63%)
Prev Close
$4.60
Open
$4.55
Day's High
$4.60
Day's Low
$4.47
Volume
7,838
Avg. Vol
65,247
52-wk High
$18.30
52-wk Low
$4.30

Chart for

About

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic... (more)

Overall

Beta: --
Market Cap(Mil.): $611.97
Shares Outstanding(Mil.): 35.48
Dividend: --
Yield (%): --

Financials

  CALA.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -1.26 -- --
ROI: -24.22 2.22 14.61
ROE: -26.14 3.86 16.34

BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma

* CALITHERA BIOSCIENCES ANNOUNCES FDA FAST TRACK DESIGNATION GRANTED TO CB-839 IN COMBINATION WITH CABOZANTINIB FOR TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:

18 Apr 2018

BRIEF-Calithera Biosciences Qtrly Net Loss From Operations $11.0 Mln

* CALITHERA BIOSCIENCES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

08 Mar 2018

BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018

* CALITHERA BIOSCIENCES INC - PLAN TO INITIATE A GLOBAL, RANDOMIZED PHASE 2 TRIAL OF CB-839 IN COMBINATION WITH CABOZANTINIB IN Q2 OF 2018 Source text for Eikon: Further company coverage:

05 Feb 2018

Competitors

  Price Chg
Agios Pharmaceuticals Inc (AGIO.OQ) $88.67 -2.39
AstraZeneca plc (AZN.L) 5,585.00 -4.00
Bayer AG (BAYGn.DE) €92.42 +0.37
Bayer AG (BAYE.F) -- --
Celgene Corporation (CELG.OQ) $85.22 +0.12
Eli Lilly And Co (LLY.N) $88.90 +0.43
GlaxoSmithKline plc (GSK.L) 1,564.60 +14.80
Merck KGaA (MRCG.DE) €84.90 -0.94
Novartis AG (NOVN.S) CHF82.02 -0.18
Pfizer Inc. (PFE.N) $37.19 -0.14

Earnings vs. Estimates